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Children with hypodiploid acute lymphoblastic leukemia (ALL) have inferior outcomes despite intensive
risk-adapted chemotherapy regimens. We describe 78 children with hypodiploid ALL who underwent
hematopoietic stem cell transplantation between 1990 and 2010. Thirty-nine (50%) patients had  43
chromosomes, 12 (15%) had 44 chromosomes, and 27 (35%) had 45 chromosomes. Forty-three (55%) pa-
tients underwent transplantation in ﬁrst remission (CR1) and 35 (45%) underwent transplantation in 
second remission (CR2). Twenty-nine patients (37%) received a graft from a related donor and 49 (63%)
from an unrelated donor. All patients received a myeloablative conditioning regimen. The 5-year proba-
bilities of leukemia-free survival, overall survival, relapse, and treatment-related mortality for the entire
cohort were 51%, 56%, 27%, and 22%, respectively. Multivariate analysis conﬁrmed that mortality risks were
higher for patients who underwent transplantation in CR2 (hazard ratio, 2.16; P ¼ .05), with number of
chromosomes  43 (hazard ratio, 2.15; P ¼ .05), and for those who underwent transplantation in the ﬁrst
decade of the study period (hazard ratio, 2.60; P ¼ .01). Similarly, treatment failure risks were higher with
number of chromosomes  43 (hazard ratio, 2.28; P ¼ .04) and the earlier transplantation period (hazarddgments on page 1277.
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P.A. Mehta et al. / Biol Blood Marrow Transplant 21 (2015) 1273e12771274ratio, 2.51; P ¼ .01). Although survival is better with advances in donor selection and supportive care,
disease-related risk factors signiﬁcantly inﬂuence transplantation outcomes.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION neutrophil recovery, deﬁned as achieving an absolute neutrophil count .5 
Chemotherapy regimens have improved signiﬁcantly
over the last 50 years, and now more than 80% of children
with acute lymphoblastic leukemia (ALL) are cured with
chemotherapy [1-7]. Children with hypodiploid ALL, how-
ever, continue to have inferior outcomes despite risk-
adapted intensive chemotherapy treatment. An early report
from Children’s Cancer Group analyzed a total of 4986 chil-
dren treated between 1988 and 1995 on Children’s Cancer
Group studies. Among these, 1880 cases had centrally
reviewed and accepted cytogenetic data and 110 cases (6%)
were classiﬁed as hypodiploid. Six-year event-free survival
(EFS) was worse in hypodiploid cases than nonhypodiploid
patients (58% versus 76%, respectively, P < .0001). Six-year
EFS estimates for patients with 45 chromosomes were 65%;
33 to 44 chromosomes, 40%; and 24 to 28 chromosomes, 25%
(log rank, P < .002). Of note, only 23 patients had fewer than
45 chromosomes [8]. More recently, a case series of pediatric
hypodiploid ALL patients with <45 chromosomes (n ¼ 139)
treated by 10 different national ALL study groups between
1986 and 1996 [9], reported an 8-year EFS of 38.5% and
overall survival (OS) of 49.8%. Patients with fewer than 44
chromosomes fared signiﬁcantly worse than those with 44
chromosomes (EFS, 30% versus 52%; P ¼ .01; OS, 37% versus
69%; P ¼ .017). Most of the patients received treatment on
higher risk regimens and, notably, there were no induction
failures, but relapses tended to occur early (within 2 years).
A similar report from the Medical Research Council
included 226 children and adults treated with chemotherapy
between 1990 and 2002 [10]. In that report, patients with
45 chromosomes were considered hypodiploid. One hun-
dred twenty-one patients had 42 to 45 chromosomes and
had acceptable survival with chemotherapy at 66%. The
majority (n ¼ 114) of these patients had 45 chromosomes,
with only 7 children in the 42 to 44 chromosome group. In
contrast, patients with 25 to 39 chromosomes had 29% sur-
vival at 3 years (P ¼ .002) and all but 1 of 14 near haploid
patients died.
The goals of the present study were to describe the
outcome of children undergoing related or unrelated donor
hematopoietic cell transplantation for hypodiploid ALL
(deﬁned as 45 or fewer chromosomes) and to identify
disease-related prognostic factors that may affect overall and
leukemia-free survival after transplantation.PATIENTS AND METHODS
Patients
The Center for International Blood and Marrow Transplant Research is a
voluntary working group of more than 450 transplantation centers world-
wide. Participating centers are required to report all consecutive trans-
plantations and compliance was ensured by on site audits. Patients are
followed longitudinally until death or lost to follow-up. Patients or their
guardians provided written informed consent. the institutional review
boards of the Medical College of Wisconsin and the National Marrow Donor
Program approved this study.Endpoints
The primary endpoint was leukemia-free survival, deﬁned as being alive
without leukemia recurrence. Death from any cause or relapse was
considered an event (treatment failure). Other outcomes studied included109/L for 3 consecutive measurements, and platelet recovery, deﬁned as
platelets 20  109/L without transfusion for 7 days. Diagnoses of grades 2
to 4 acute graft-versus-host disease (GVHD) and chronic GVHD were based
on published criteria [11,12]. Treatment-related mortality (TRM) was deﬁned
as death not attributed to relapse, and relapse was deﬁned as morphologic
recurrence of leukemia. Surviving patients were censored at last follow-up
and death from any cause was considered an event.Statistical Methods
The probabilities of neutrophil and platelet recovery, acute and chronic
GVHD, TRM, and relapse were calculated with the use of the cumulative-
incidence function method [13]. For TRM, relapse was the competing
event and for relapse, TRM, the competing event. The probabilities of
leukemia-free and OS were calculated using the Kaplan-Meier estimator
[14]. Cox regression multivariate models were built for leukemia-free sur-
vival, OS, TRM, and relapse [15]. Due to the relatively modest sample size,
only variables known to inﬂuence relapse, TRM, leukemia-free and OS were
tested, including number of chromosomes (43 or fewer versus 44 or 45);
disease status (complete remission [CR] 2 and 3 versus CR1); with t(9;22)
(yes versus no); year of transplantation (2000 to 2010 versus 1990 to 1999).
A P value of .05 or less was considered statistically signiﬁcant. All P values
are 2 sided, and analyses were performed using SAS software, version 9.1
(SAS Institute, Cary, NC).RESULTS
Patients, Disease, and Transplantation Characteristics
Patients and disease characteristics of the 78 patients
ages 18 years with hypodiploid ALL who received a trans-
plant from HLA-matched siblings, HLA-mismatched rela-
tives, HLA-matched or HLA-mismatched unrelated donors
between 1990 and 2010 are shown in Table 1. Twenty-nine of
78 patients received grafts from a related donor and 49 pa-
tients received their grafts from an unrelated donor. Median
age at transplantation was 10 years (range, 3 to 18). Fifty
percent of patients had 43 or fewer chromosomes, 15% had
44 chromosomes, and 35% had 45 chromosomes. Nine of 78
patients were reported to have a Philadelphia chromosome,
but only 2 of these patients had 43 or fewer chromosomes.
Fifty-ﬁve percent of transplantations occurred in CR1 and
38% in CR2. Among patients who underwent transplantation
in CR2, 19 of 26 (66%) had a short duration CR1 (CR1  36
months). The median follow-up of surviving patients is 80
(range, 14 to 240) months.
Transplantation characteristics are summarized in
Table 2. Twenty-nine percent of patients received their graft
from a matched sibling, 8% from other relatives, and 63%
from unrelated donors. Donor-recipient pairs considered
well matched were deﬁned as having no known disparity at
human leukocyte antigen (HLA) -A, -B, -C, and -DRB1; those
considered mismatched were deﬁned as having 1, 2, or more
disparities [16]. Among recipients of matched sibling trans-
plants, 1 received umbilical cord blood and the remaining
received bone marrow (n ¼ 20) or peripheral blood (n ¼ 1).
The corresponding distribution of graft type for unrelated
donor transplantation was 15, 29, and 5, respectively. Over
one half of unrelated donor transplantations were HLA
mismatched. Mismatched related donors received bone
marrow (n ¼ 5) or peripheral blood (n ¼ 1). All recipients
received a myeloablative preparative regimen with 95%
of patients receiving total body irradiationecontaining
Table 2
Transplantation Characteristics
Characteristics n (%)
Donor and graft Source
Related
HLA-matched sibling 23 (29)
Other relative 6 (8)
Unrelated
Matched unrelated donor 18 (23)
Mismatched unrelated donor 16 (21)
Matched cord blood 5 (6)
Mismatched cord blood 10 (13)
Conditioning regimen
Total body irradiation þ cyclophosphamide 66 (85)
Total body irradiation þ other agents 8 (10)
Busulfan þ cyclophosphamide 4 (5)
Antithymocyte globulin or alemtuzumab
No 50 (64)
Yes 27 (35)
Not reported 1 (1)
GVHD prophylaxis
Ex vivo T cell depletion 10 (13)
Tacrolimus-containing 14 (18)
Cyclosporine-containing 53 (68)
Not reported 1 (1)
Year of transplantation
1990-1999 40 (51)
2000-2010 38 (49)
Table 1
Patient and Disease Characteristics
Characteristics n (%)
No. of patients 78
No. of centers 52
Age at transplantation, yr
5 11 (14)
6-10 30 (38)
11-15 22 (28)
16-18 15 (19)
Sex
Male 47 (60)
Female 31 (40)
National Cancer Institute risk group
Good risk 27 (35)
Poor risk 44 (56)
Unknown 7 (9)
Additional cytogenetic abnormalities*
t(9;22) abnormality 9 (12)
t(4,11) 1 (1)
Monosomy 7 25 (32)
Monosomy 5/del 5q- 10 (13)
Other monosomies 11 (14)
Trisomy 8/14 12 (15)
Lansky performance score before transplantation
<90 9 (12)
90-100 66 (85)
Unknown 3 (4)
No. of chromosomes
43 39 (50)
44 12 (15)
45 27 (35)
Disease status at transplantation
CR1 43 (55)
CR2 29 (38)
CR3 6 (7)
Recipient cytomegalovirus serostatus
Negative 43 (55)
Positive 35 (44)
* Not mutually exclusive. Most patients had more than 1 cytogenetic
abnormality.
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inhibitorecontaining GVHD prophylaxis.Table 3
Unadjusted Probabilities of Outcomes after Transplantation for the Entire
Cohort
Outcome Probability (95% CI)
Day 28 neutrophil recovery 79% (70-87)
Day 100 platelet recovery 78% (67-87)
Day 100 grade 2 to 4 acute GVHD 56% (45-67)
5-Year chronic GVHD 31% (22-42)
5-Year relapse 27% (18-38)
5-Year TRM 22% (14-32)
5-Year leukemia-free survival 51% (40-62)
5-Year OS 56% (44-67)Outcomes
The results of univariate analysis for the entire population
are shown in Table 3. The 5-year leukemia-free survival, OS,
relapse, and TRM were 51%, 56%, 27%, and 22%, respectively.
Results of multivariate analysis for leukemia-free survival,
OS, relapse and TRM are presented in Table 4. Hypodiploid
(number of chromosomes 43 or fewer) was associated with
higher mortality and treatment failure. Other factors asso-
ciated with higher mortality included transplantation in
second or third CR and transplantation period 1990 to 1999.
The probability of 5-year OS adjusted for disease status and
transplantation period for patients with 43 or fewer chro-
mosomes was 38% (95% conﬁdence interval [CI], 24 to 52)
and for those with 44 or 45 chromosomes, 71% (95% CI, 56 to
82); P ¼ .001 (Figure 1). Treatment failure (inverse of
leukemia-free survival) was higher for transplantation
period 1990 to 1999. The effect of disease status on treatment
failure did not reach the level of signiﬁcance set for this
analysis. The probability of 5-year leukemia-free survival
adjusted for disease status and transplantation period for
patients with 43 or fewer chromosomes was 37% (95% CI, 23
to 51) and for those with 44 or 45 chromosomes, 64% (95% CI,
48 to 76); P ¼ .01 (Figure 2). None of the variables tested
attained the level of signiﬁcance set for this analyses for TRM
and relapse.At the last follow-up (median, 80 months; range, 14 to
240 months), 35 (45%) patients had died. Seventeen (22%)
died of recurrent disease, the predominant cause of treat-
ment failure. Other causes of death include GVHD (n ¼ 5),
infection (n ¼ 7), organ failure (n ¼ 4), and other causes (n ¼
2). Two patients developed Epstein-Barr viruseassociated
lymphoma at 1.5 months and 10 years after transplantation.
The patient who developed Epstein-Barr viruseassociated
lymphoma at 1.5 months died from an infection 3 months
after transplantation and the other patient is alive, 16 years
after transplantation. There were 3 reported second malig-
nant neoplasms: 1 patient with tumor of the parotid gland, 1
with a brain tumor, and 1 with cancer of the thyroid gland at
5.5 years, 7.5 years, and 3.3 years, respectively, after trans-
plantation. Two of these patients are alive and the patient
with brain tumor died 1 year after diagnosis.DISCUSSION
The remarkable progress achieved in the treatment of
childhood ALL is the result of a series of large-scale clinical
studies conducted by cooperative clinical trials groups. In
addition, biologic investigations have improved risk group
identiﬁcation [17] and allowed administration of risk-
adapted therapy. These advances, combined with a better
understanding of disease mechanisms and the ability to
Figure 2. The 5-year probability of leukemia-free survival by number of
chromosomes and adjusted for disease status at transplantation and trans-
plantation period.
Table 4
Results of Multivariate Analysis
Outcome Hazard Ratio (95% CI) P Value
TRM
Disease status
CR1 1.00
CR2/3 1.84 (.60-5.60) .28
No. of chromosomes
44 or 45 1.00
43 or fewer 1.81 (.59-5.57) .30
Year of transplantation
2000-2010 1.00
1990-1999 2.68 (.93-7.75) .06
Relapse
Disease status
CR1 1.00
CR2/3 2.23 (.76-6.56) .14
No. of chromosomes
44 or 45 1.00
43 or fewer 2.82 (.92-8.61) .07
Year of transplantation
2000-2010 1.00
1990-1999 2.46 (.98-1.08) .06
Treatment failure
Disease status
CR1 1.00
CR2/3 2.02 (.93-4.36) .07
No. of chromosomes
44 or 45 1.00
43 or fewer 2.28 (1.04-5.01) .04
Year of transplantation
2000-2010 1.00
1990-1999 2.51 (1.27-5.00) .01
Overall mortality
Disease status
CR1 1.00
CR2/3 2.28 (1.02-5.10) .04
No. of chromosomes
44 or 45 1.00
43 or fewer 2.69 (1.17-6.15) .02
Year of transplantation
2000-2010 1.00
1990-1999 2.60 (1.27-5.31) .01
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important changes in transplantation techniques, donor
availability, donor-recipient HLA match, and other support-
ive care measures. Together, these events have led to changes
in indications for transplantation for childhood ALL as well as
associated outcomes. Perhaps the best example of this is the
use of the tyrosine kinase inhibitor imatinib in childhood
ALL, which has led to current data suggesting that trans-
plantation is routinely not needed for Philadelphia-positive
ALL in CR1 [18].Figure 1. The 5-year probability of OS by number of chromosomes and
adjusted for disease status at transplantation and transplantation period.Our goal in the current study was to identify factors that
predict for better OS and leukemia-free survival in children
with hypodiploid ALL undergoing allogeneic HSCT. Data
describing outcomes after transplantation for these patients
are sparse. A previous Children’s Oncology group (COG)
study described 9 patients who underwent HSCT during the
study period of 10 years [9]. Patients underwent trans-
plantation in ﬁrst CR and 5 had an adverse event after
transplantation. The current report, with its larger popula-
tion, identiﬁed 3 prognostic factors; 43 or fewer chromo-
somes, second or subsequent CR, and transplantation before
2000 as predictive for lower OS and 43 or fewer chromo-
somes and transplantation before 2000 predictive for lower
leukemia-free survival. Although the risks of leukemia
recurrence were higher for patients with 43 or fewer chro-
mosomes, second or subsequent CR and transplantation
before 2000, this did not reach the level of signiﬁcance set for
the current analysis. The lack of a statistically signiﬁcant
association between these factors and leukemia recurrence is
likely because of the modest sample size.
A limitation of the current analysis is that we report
transplantation outcomes and, therefore, the results are
applicable only to those patients who attained remission and
proceeded to transplantation. The series on hypodiploid ALL
from the COG include patients treated on their chemo-
therapy trials and, thereby, captured events beginning from
time of diagnosis. Therefore, it is not possible to compare the
survival and leukemia-free survival rates from the current
analysis to the COG studies. To be able to assess whether
transplantation is indeed superior to intensive chemo-
therapy would require a carefully planned clinical trial that
randomly allocates those beyond CR1 with 43 or fewer
chromosomes to transplantation or continuing chemo-
therapy. Such a trial will only be feasible with the coopera-
tion of several international pediatric consortia, such as the
COG and others. In 2 recent COG reviews, which included
patients with hypodiploid ALL enrolled on their trials, min-
imal residual disease  .01% at the end of induction was
associated with inferior outcome. We are unable to evaluate
the effect of minimal residual disease status at end of in-
duction therapy or before transplantation, as this was not
systematically tested for in our cohort [19,20].
A recent publication by Holmfeldt et al. reported novel
genomic properties of childhood hypodiploid ALL [21].
Marked enrichment for Ras-pathway, RB1, and TP53 alter-
ations were seen in patients with hypodiploid ALL. A high
frequency of TP53 alterations in both pediatric and adult
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seen, suggesting that mutation of TP53 is a signiﬁcant event
in the pathogenesis of low-hypodiploid ALL. Furthermore,
almost one half of the TP53 mutations identiﬁed in pediatric
low-hypodiploid ALL were present as heterozygous muta-
tions in remission bone marrow or peripheral blood and in
puriﬁed normal T cell populations, and most of these are
known Li-Fraumeni syndromeeassociated mutations [22].
The frequency of secondary malignancy in our cohort was
signiﬁcant and raises concern that possible excess of malig-
nancy will be seen on longitudinal follow-up. Future studies
should look directly for TP53 mutations, and longer follow-
up will better deﬁne the risk of subsequent cancers.
Although the current analyses has several limitations,
including its modest sample size, transplantation period that
spanned over 2 decades, and our inability to determine why
some transplantations occurred in ﬁrst CR and others in
second or subsequent CR, the analyses conﬁrms a worse
outcome for patients with 43 or fewer chromosomes
compared with 44 or 45 chromosomes and transplantation.
This information is relevant for physicians, patients, and
their families, and for future clinical trial planning to deter-
mine a role for allogeneic transplant in the era of risk-
adapted therapy for ALL.
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